Yeluri Formulations Private Limited

Yeluri Formulations Private Limited, established on January 15, 1997, is a privately held pharmaceutical company headquartered in Hyderabad, Telangana, India. The company specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. It operates under the Corporate Identification Number (CIN) U24230TG1997PTC026188 and is registered with the Registrar of Companies, Hyderabad.

As of March 28, 2024, Yeluri Formulations reported an authorized capital of ₹3.15 crore and a paid-up capital of ₹2.33 crore. The company employs approximately 86 professionals. The latest Annual General Meeting (AGM) was held on September 30, 2024, with the balance sheet filed on March 31, 2024.

Yeluri Formulations operates manufacturing facilities in Hyderabad, Telangana, India. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding plant capacities and specialized manufacturing capabilities are not publicly disclosed.

The leadership team at Yeluri Formulations includes:

• Yeluri Hari Prasad – Managing Director, appointed on April 1, 2009.
• Eluri Nageswara Rao – Director, appointed on April 1, 2009.
• Eluri Sridevi – Director, appointed on April 1, 2009.
• Manogna Yeluri – Additional Director, appointed on June 28, 2021.

These individuals play pivotal roles in steering the company's strategic direction and operations.

Yeluri Formulations has engaged in exporting its pharmaceutical products to various international markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's export data from 2022 to 2026 indicates a total export value of $1.9 million USD across 39 shipments, with products spanning two therapeutic categories. Notably, the top two exported products are Metronidazole and Ivermectin, with respective export values of $1.6 million and $234,000. However, specific details regarding regulatory filings, approvals, and market access status in these regions are not publicly available.

Yeluri Formulations has also extended its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's export data from 2022 to 2026 reflects a total export value of $1.9 million USD across 39 shipments, with products spanning two therapeutic categories. The top two exported products are Metronidazole and Ivermectin, with respective export values of $1.6 million and $234,000. While the company's engagement in these regions suggests a strategic focus on emerging markets, specific details regarding WHO prequalification or other certifications enabling access to these markets are not publicly disclosed.

Yeluri Formulations' export data from 2022 to 2026 indicates a total export value of $1.9 million USD across 39 shipments, with products spanning two therapeutic categories. The top two exported products are Metronidazole and Ivermectin, with respective export values of $1.6 million and $234,000. This portfolio concentration, with the top five products accounting for 100% of exports, suggests a focused geographic strategy. However, specific details regarding the company's diversification efforts, concentration risks, and strategic direction are not publicly available.

Specific details regarding Yeluri Formulations' FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed. The company's export data from 2022 to 2026 indicates a total export value of $1.9 million USD across 39 shipments, with products spanning two therapeutic categories. The top two exported products are Metronidazole and Ivermectin, with respective export values of $1.6 million and $234,000. However, without specific regulatory filings and approvals, it is challenging to assess the company's standing in the U.S. market.

Specific information regarding Yeluri Formulations' WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly available. The company's export data from 2022 to 2026 indicates a total export value of $1.9 million USD across 39 shipments, with products spanning two therapeutic categories. The top two exported products are Metronidazole and Ivermectin, with respective export values of $1.6 million and $234,000. However, without access to specific certifications, it is difficult to evaluate the company's compliance with international quality standards.

Yeluri Formulations holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has approvals from state drug controllers. The company has also obtained export No Objection Certificates (NOCs) for its pharmaceutical products. Specific details regarding these licenses and approvals are not publicly disclosed. The company's export data from 2022 to 2026 indicates a total export value of $1.9 million USD across 39 shipments, with products spanning two therapeutic categories. The top two exported products are Metronidazole and Ivermectin, with respective export values of $1.6 million and $234,000.

As of March 28, 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Yeluri Formulations. The company's export data from 2022 to 2026 indicates a total export value of $1.9 million USD across 39 shipments, with products spanning two therapeutic categories. The top two exported products are Metronidazole and Ivermectin, with respective export values of $1.6 million and $234,000. The absence of regulatory actions suggests a favorable compliance record.

Yeluri Formulations operates in the competitive pharmaceutical industry, focusing on finished formulations such as tablets, capsules, syrups, and injections. The company's export data from 2022 to 2026 indicates a total export value of $1.9 million USD across 39 shipments, with products spanning two therapeutic categories. The top two exported products are Metronidazole and Ivermectin, with respective export values of $1.6 million and $234,000. While specific market share comparisons and head-to-head analyses with competitors are not publicly available, the company's product portfolio and export activities suggest a presence in the global pharmaceutical market.

Yeluri Formulations' key differentiators include its focused product portfolio, with the top five products accounting for 100% of exports, and its engagement in both regulated and emerging markets. The company's export data from 2022 to 2026 indicates a total export value of $1.9 million USD across 39 shipments, with products spanning two therapeutic categories. The top two exported products are Metronidazole and Ivermectin, with respective export values of $1.6 million and $234,000. These factors highlight the company's strategic approach to market penetration and product specialization.

Yeluri Formulations' strategic direction appears to focus on the export of finished pharmaceutical formulations, with a concentrated product portfolio and engagement in both regulated and emerging markets. The company's export data from 2022 to 2026 indicates a total export value of $1.9 million USD across 39 shipments, with products spanning two therapeutic categories. The top two exported products are Metronidazole and Ivermectin, with respective export values of $1.6 million and $234,000. While specific details regarding the company's future outlook are not publicly available, its current strategic position suggests a commitment to expanding its global footprint in the pharmaceutical industry.

Yeluri Formulations has demonstrated a consistent track record in exporting pharmaceutical products, with a total export value of $1.9 million USD across 39 shipments from 2022 to 2026. The top two exported products are Metronidazole and Ivermectin, with respective export values of $1.6 million and $234,000. This consistency indicates reliability in fulfilling export commitments. However, specific indicators of reliability, such as on-time delivery rates and customer satisfaction metrics, are not publicly disclosed.

Importers should verify the following certifications when considering Yeluri Formulations as a supplier:

• FDA Approval: Confirm that the company's products are